Editorial Commentary
Overall survival of ADAURA: game, set, and match?
AME Clinical Trials Review
2023;
1:
10
(25 October 2023)
Editorial Commentary
What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?
AME Clinical Trials Review
2023;
1:
9
(25 October 2023)
Editorial Commentary
Segmentectomy for partially solid non-small cell lung cancer: what counts—the resection or the patient?
AME Clinical Trials Review
2023;
1:
8
(25 October 2023)
Editorial Commentary
Real world data are needed to establish safety of adjuvant immune checkpoint inhibitors after pneumonectomy
AME Clinical Trials Review
2023;
1:
7
(25 October 2023)
Editorial Commentary
Neoadjuvant immunotherapy for resectable non-small cell lung cancer—what lies ahead
AME Clinical Trials Review
2023;
1:
6
(25 October 2023)
Editorial Commentary
Towards better outcomes: segmentectomy for ground-glass opacity-dominant non-small cell lung cancer 3 cm or less—insights from JCOG1211
AME Clinical Trials Review
2023;
1:
5
(25 October 2023)
Editorial Commentary
The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
4
(25 October 2023)
Editorial Commentary
An ever-stronger case for circulating tumor DNA monitoring in ALK+ lung cancer
AME Clinical Trials Review
2023;
1:
3
(25 October 2023)
Editorial Commentary
Editorial commentary: the importance of staging hasn’t changed, but the procedure of choice has
AME Clinical Trials Review
2023;
1:
2
(25 October 2023)
Editorial
Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review
AME Clinical Trials Review
2023;
1:
1
(25 October 2023)